Evidence map›Paper›PMID 37799130›Full record

ArticleOpen forum infectious diseases2023

Effectiveness of a Messenger RNA Vaccine Booster Dose Against Coronavirus Disease 2019 Among US Healthcare Personnel, October 2021-July 2022.

Ian D Plumb, Nicholas M Mohr, Melissa Hagen, Ryan Wiegand, Ghinwa Dumyati, Karisa K Harland, Anusha Krishnadasan, Jade James Gist, Glen Abedi, Katherine E Fleming-Dutra and 27 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open forum infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 20 institutions in 1 country.

Ian D PlumbNational Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0003-4747-381X
Nicholas M MohrDepartment of Emergency Medicine, University of Iowa, Iowa City, Iowa, USA.
Melissa HagenNational Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Ryan WiegandNational Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Ghinwa DumyatiNew York State Emerging Infections Program, University of Rochester Medical Center, Rochester, New York, USA.ORCID https://orcid.org/0000-0002-3634-2841
Karisa K HarlandDepartment of Emergency Medicine, University of Iowa, Iowa City, Iowa, USA.ORCID https://orcid.org/0000-0001-9482-8447
Anusha KrishnadasanDepartment of Emergency Medicine, Olive View-UCLA Education and Research Institute, Los Angeles, California, USA.
Jade James GistNational Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Glen AbediNational Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Katherine E Fleming-DutraNational Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-4862-0650
Nora CheaNational Center for Emerging and Zoonotic Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Jane LeeHealthcare-Associated Infections, California Emerging Infections Program, Oakland, California, USA.
Devra BarterHealthcare-associated Infections / Antimicrobial Resistance Program, Colorado Department of Public Health & Environment, Denver, Colorado, USA.
Monica BrackneyConnecticut Emerging Infections Program, Yale School of Public Health, New Haven, Connecticut, USA.
Scott K FridkinGeorgia Emerging Infections Program and Emory University School of Medicine, Atlanta, Georgia, USA.
Lucy E WilsonMaryland Emerging Infections Program, Maryland Department of Health, and University of Maryland, Baltimore County, Baltimore, Maryland, USA.
Sara A LovettInfectious Disease Epidemiology, Prevention and Control Divison, Minnesota Department of Health, St. Paul, Minnesota, USA.
Valerie OcampoPublic Health Division, Oregon Health Authority, Portland, Oregon, USA.
Erin C PhippsNew Mexico Emerging Infections Program, University of New Mexico, Albuquerque, New Mexico, USA.
Tiffanie M MarcusDepartment of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Howard A SmithlineDepartment of Emergency Medicine, University of Massachusetts Chan Medical School - Baystate, Springfield, Massachusetts, USA.
Peter C HouDepartment of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Lilly C LeeEmergency Medicine, Jackson Memorial Hospital, Miami, Florida, USA.
Gregory J MoranDavid Geffen School of Medicine, UCLA, Los Angeles, California, USA.
Elizabeth KrebsEmergency Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, USA.
Mark T SteeleDepartment of Emergency Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Stephen C LimSection of Emergency Medicine, University Medical Center New Orleans, LSU Health Sciences Center, New Orleans, Louisiana, USA.
Walter A SchradingDepartment of Emergency Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Brian ChinnockDepartment of Emergency Medicine, University of California San Francisco, Fresno, California, USA.
David G BeiserSection of Emergency Medicine, University of Chicago, Chicago, Illinois, USA.
Brett FaineDepartment of Emergency Medicine, University of Iowa, Iowa City, Iowa, USA.
John P HaranDepartment of Emergency Medicine, University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
Utsav NandiDepartment of Emergency Medicine, University of Mississippi Medical Center, Jackson, Mississippi, USA.
Anne K ChipmanEmergency Department, University of Washington, Seattle, Washington, USA.
Frank LoVecchioEmergency Medicine, Valleywise Health Medical Center, Phoenix, Arizona, USA.
David A TalanDavid Geffen School of Medicine, UCLA, Los Angeles, California, USA.ORCID https://orcid.org/0000-0002-7048-8086
Tamara PilishviliNational Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Centers for Disease Control and Prevention · USUniversity of Iowa · USUniversity of California, Los Angeles · USUniversity of Massachusetts Chan Medical School · USBrigham and Women's Hospital · USColorado Department of Public Health and Environment · USEducation and Research Institute · USEmory University · USHealthwise · USJackson Memorial Hospital · USMaryland Department of Health · USMinnesota Department of Health · USOregon Health Authority · USThomas Jefferson University Hospital · USUniversity Medical Center New Orleans · USUniversity of Alabama at Birmingham · USUniversity of California, San Francisco · USUniversity of Chicago · USUniversity of Mississippi Medical Center · USUniversity of Missouri–Kansas City · US

Funding

The University of Iowa Clinical and Translational Science AwardUL1TR002537 · NCATS · UNIVERSITY OF IOWA · PI HANSEN, MARLAN R, WINOKUR, PATRICIA · 2018 to 2022
$20.0M
ACL HHS U01CK000480NCATS NIH HHS UL1 TR002537NCEZID CDC HHS U01 CK000643
6 · The paper itself

Abstract

Background: Protection against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019 [COVID-19]) can limit transmission and the risk of post-COVID conditions, and is particularly important among healthcare personnel. However, lower vaccine effectiveness (VE) has been reported since predominance of the Omicron SARS-CoV-2 variant. Methods: We evaluated the VE of a monovalent messenger RNA (mRNA) booster dose against COVID-19 from October 2021 to June 2022 among US healthcare personnel. After matching case-participants with COVID-19 to control-participants by 2-week period and site, we used conditional logistic regression to estimate the VE of a booster dose compared with completing only 2 mRNA doses >150 days previously, adjusted for multiple covariates. Results: Among 3279 case-participants and 3998 control-participants who had completed 2 mRNA doses, we estimated that the VE of a booster dose against COVID-19 declined from 86% (95% confidence interval, 81%-90%) during Delta predominance to 65% (58%-70%) during Omicron predominance. During Omicron predominance, VE declined from 73% (95% confidence interval, 67%-79%) 14-60 days after the booster dose, to 32% (4%-52%) ≥120 days after a booster dose. We found that VE was similar by age group, presence of underlying health conditions, and pregnancy status on the test date, as well as among immunocompromised participants. Conclusions: A booster dose conferred substantial protection against COVID-19 among healthcare personnel. However, VE was lower during Omicron predominance, and waning effectiveness was observed 4 months after booster dose receipt during this period. Our findings support recommendations to stay up to date on recommended doses of COVID-19 vaccines for all those eligible.

Indexed as

COVID-19healthcare personnelOmicronSARS-CoV-2vaccine effectiveness

Identifiers

PMID37799130
PMCPMC10549208
OpenAlexW4386543987

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.